Literature DB >> 2963964

Radioreceptor binding reveals the potencies of N,N-disubstituted 2-aminotetralins as D2 dopamine agonists.

P M Beart1, C J Cook, M Cincotta, D J de Vries, P Tepper, D Dijkstra, A S Horn.   

Abstract

The affinity of a series of N,N-disubstituted 2-aminotetralins for the rat striatal D2 dopamine receptor labelled by [3H]spiperone has been determined. Displacement data for the more potent 2-aminotetralins were better described by a model where the compounds competed for [3H]spiperone at two sites. The high affinity component accounted for approximately 80% of the total sites. Displacement curves for all 2-aminotetralins were shifted to the right by 100 microM guanosine-5'-triphosphate; a result attributable to the redistribution of 13-47% of the sites to a low affinity form. These data are consistent with the N,N-disubstituted 2-aminotetralins being agonists at the D2 dopamine receptor. In particular, the affinities of the 5-hydroxy-2-aminotetralins were as high as those of traditional dopamine agonists.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2963964     DOI: 10.1007/bf00169304

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  38 in total

1.  Interactions of agonists with D-2 dopamine receptors: evidence for a single receptor population existing in multiple agonist affinity-states in rat striatal membranes.

Authors:  M W Hamblin; S E Leff; I Creese
Journal:  Biochem Pharmacol       Date:  1984-03-15       Impact factor: 5.858

2.  A practical computer-based approach to the analysis of radioligand binding experiments.

Authors:  G A McPherson
Journal:  Comput Programs Biomed       Date:  1983 Aug-Oct

Review 3.  Two dopamine receptors: biochemistry, physiology and pharmacology.

Authors:  J C Stoof; J W Kebabian
Journal:  Life Sci       Date:  1984-12-03       Impact factor: 5.037

4.  Activity of two new potent dopaminergic agonists at the striatal and anterior pituitary levels.

Authors:  C Euvrard; L Ferland; T Di Paolo; M Beaulieu; F Labrie; C Oberlander; J P Raynaud; J R Boissier
Journal:  Neuropharmacology       Date:  1980-04       Impact factor: 5.250

5.  The dopamine hypothesis: an overview of studies with schizophrenic patients.

Authors:  J L Haracz
Journal:  Schizophr Bull       Date:  1982       Impact factor: 9.306

6.  Pharmacological profiles of three new, potent and selective dopamine receptor agonists: N-0434, N-0437 and N-0734.

Authors:  J Van der Weide; J B De Vries; P G Tepper; A S Horn
Journal:  Eur J Pharmacol       Date:  1986-06-17       Impact factor: 4.432

7.  Dopamine D2 receptor binding sites for agonists. A tetrahedral model.

Authors:  P Seeman; M Watanabe; D Grigoriadis; J L Tedesco; S R George; U Svensson; J L Nilsson; J L Neumeyer
Journal:  Mol Pharmacol       Date:  1985-11       Impact factor: 4.436

8.  Synthesis and radioreceptor binding activity of N-0437, a new, extremely potent and selective D2 dopamine receptor agonist.

Authors:  A S Horn; P Tepper; J Van der Weide; M Watanabe; D Grigoriadis; P Seeman
Journal:  Pharm Weekbl Sci       Date:  1985-10-25

9.  Magnesium ions reveal nanomolar potency of dopamine at [3H]spiperone labelled D-2 receptors in rat corpus striatum.

Authors:  D J De Vries; P M Beart
Journal:  Eur J Pharmacol       Date:  1985-03-12       Impact factor: 4.432

10.  Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary.

Authors:  A Enjalbert; J Bockaert
Journal:  Mol Pharmacol       Date:  1983-05       Impact factor: 4.436

View more
  1 in total

1.  Pharmacological profile of non-hydroxylated and ether derivatives of the potent D2-selective agonist N-0437.

Authors:  J M Jansen; I den Daas; H Rollema; P J Swart; P G Tepper; J B de Vries; A S Horn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-02       Impact factor: 3.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.